Search

Your search keyword '"Claudia A. M. Fulgenzi"' showing total 2 results
Start Over Author "Claudia A. M. Fulgenzi" Journal liver international
2 results on '"Claudia A. M. Fulgenzi"'

1. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study

Author

Thomas Talbot, Antonio D'Alessio, Matthias Pinter, Lorenz Balcar, Bernhard Scheiner, Thomas U. Marron, Tomi Jun, Sirish Dharmapuri, Celina Ang, Anwaar Saeed, Hannah Hildebrand, Mahvish Muzaffar, Claudia A. M. Fulgenzi, Suneetha Amara, Abdul Rafeh Naqash, Anuhya Gampa, Anjana Pillai, Yinghong Wang, Uqba Khan, Pei‐Chang Lee, Yi‐Hsiang Huang, Bertram Bengsch, Dominik Bettinger, Yehia I. Mohamed, Ahmed Kaseb, Tiziana Pressiani, Nicola Personeni, Lorenza Rimassa, Naoshi Nishida, Masatoshi Kudo, Arndt Weinmann, Peter R. Galle, Ambreen Muhammed, Alessio Cortellini, Arndt Vogel, and David J. Pinato

Subjects
Hepatology
Published
2023
Full Text
View/download PDF

2. Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

Author

Mathew Vithayathil, Antonio D'Alessio, Claudia A. M. Fulgenzi, Naoshi Nishida, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Anwaar Saeed, Brooke Wietharn, Hannah Hildebrand, Linda Wu, Celina Ang, Thomas U. Marron, Arndt Weinmann, Peter R. Galle, Dominik Bettinger, Bertram Bengsch, Arndt Vogel, Lorenz Balcar, Bernhard Scheiner, Pei‐Chang Lee, Yi‐Hsiang Huang, Suneetha Amara, Mahvish Muzaffar, Abdul Rafeh Naqash, Antonella Cammarota, Nicola Personeni, Tiziana Pressiani, Matthias Pinter, Alessio Cortellini, Masatoshi Kudo, Lorenza Rimassa, David J. Pinato, and Rohini Sharma

Subjects
YOUNGER, Carcinoma, Hepatocellular, HEPATECTOMY, Antibodies, Monoclonal, Humanized, IMMUNOSENESCENCE, ADJUVANT CHEMOTHERAPY, Antineoplastic Combined Chemotherapy Protocols, Humans, anti-vascular endothelial growth factor, RADIOFREQUENCY ABLATION, ELDERLY-PATIENTS, Aged, Science & Technology, Gastroenterology & Hepatology, Hepatology, cirrhosis, Liver Neoplasms, 1103 Clinical Sciences, CANCER, Bevacizumab, SORAFENIB, checkpoint inhibitor, anti-programmed death-ligand, immunotherapy, Life Sciences & Biomedicine, PLUS BEVACIZUMAB
Abstract

Background and Aims Combination atezolizumab/bevacizumab is the gold standard for first-line treatment of unresectable hepatocellular carcinoma (HCC). Our study investigated the efficacy and safety of combination therapy in older patients with HCC. Methods 191 consecutive patients from eight centres receiving atezolizumab and bevacizumab were included. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in older (age ≥ 65 years) and younger (age

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results